For prophylaxis of graft rejection
CCG (HRG included)
Dailiport modified release oral capsules are recommended for all patients who are newly prescribed modified release tacrolimus for transplant rejection – RAG status RED for new patients
Dailiport modified release capsules are not bioequivalent to Adoport immediate release capsules and do not replace Adoport capsules.
Existing patients using Advagraf modified release capsules will remain on Advagraf and are not routinely switched to Dailiport. If a prescriber considers that switching a patient to a different brand of oral tacrolimus would be of benefit, the change requires careful supervision and therapeutic monitoring by an appropriate specialist.
Reason for decision: